Abingdon HealthABDXF -1.75%49 Receivables Turnover is 2.64 as of Dec. 2025. GuruFocus rates ABDXF with a GF Score™ of 49/100 and a GF Value™ of $0.21 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, Abingdon Health ranks better than 54.46% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Abingdon Health's Revenue for the
six
months ended in Dec. 2025 was $5.67 Mil. Abingdon Health's average Accounts Receivable for the
six
months ended in Dec. 2025 was $2.15 Mil.
Hence, Abingdon Health's Receivables Turnover for the
six
months ended in Dec. 2025 was 2.64.
Abingdon Health (OTCPK:ABDXF) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Abingdon Health Receivables Turnover Related Terms
Abingdon Health Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Abingdon Health's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABDXF vs TMO, DHR, IDXX: Receivables Turnover Comparison
For the Diagnostics & Research subindustry, Abingdon Health's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abingdon Health Receivables Turnover vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Abingdon Health's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Abingdon Health's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abingdon Health (ABDXF) has a Receivables Turnover of 2.64 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Abingdon Health and its competitors. According to the industry distribution chart, Abingdon Health ranks #92 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 45.5%.
Is Abingdon Health's Receivables Turnover too high?
Abingdon Health's current Receivables Turnover is 2.64. The Medical Diagnostics & Research industry median Receivables Turnover is 5.40. Abingdon Health's value of 2.64 is 51.1% below this industry median. Based on the distribution chart, Abingdon Health ranks #92 out of 202 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Abingdon Health has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Abingdon Health's Receivables Turnover compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Abingdon Health ranks #92 out of 202 companies for Receivables Turnover. This puts Abingdon Health in the upper half of its industry. The industry median Receivables Turnover is 5.40. Abingdon Health's value of 2.64 is 51.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Diagnostics & Research company?
The median Receivables Turnover among Medical Diagnostics & Research companies is 5.40, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abingdon Health's current Receivables Turnover of 2.64 is 51.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Abingdon Health and its competitors. For the Medical Diagnostics & Research industry, the median Receivables Turnover is 5.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abingdon Health's current Receivables Turnover is 2.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abingdon Health stock overvalued right now?
Based on GuruFocus' analysis, Abingdon Health (ABDXF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.21, compared to a current price of $0.14 — trading 35.7% below its estimated fair value. The current Receivables Turnover is 2.64 and 51.1% below the Medical Diagnostics & Research industry median of 5.40. Abingdon Health's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Abingdon Health (ABDXF), the current Receivables Turnover is 2.64 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abingdon Health (ABDXF) Overvalued in 2026?
Based on GuruFocus' analysis, Abingdon Health stock appears to be undervalued.
The current stock price of $0.14 is trading 35.7% below its estimated GF Value™ of $0.21.
GuruFocus considers Abingdon Health to be Possible Value Trap.
Key valuation signals for ABDXF:
Receivables Turnover: 2.64
GF Value™: $0.21 vs. price of $0.14 (35.7% below fair value)
Industry Position: 51.1% below the Medical Diagnostics & Research median (#92 of 202)
No single metric tells the full story. See the ABDXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abingdon Health PLC develops, manufactures, and distributes diagnostic devices and provides regulatory consultancy to diagnostics businesses. It offers integrated lateral flow CRO/CDMO services covering feasibility, manufacturing, packaging, kitting, documentation, and commercial support. Segments include Contract Development (milestone-based third-party work, revenue over time by completion), Contract Manufacturing (development/manufacturing via daily consultancy, revenue at customer control point), Product Sales (AbC-19TM, Pocket Diagnostic, PCRD tests, research antibodies, carriage; point in time), and Regulatory Services (IVD/medical device compliance, revenue over time), with key revenue from Regulatory Services. It operates in the UK, USA/Canada, Europe, and rest of world.
49GF Score
Get the complete analysis for ABDXF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABDXF has been successfully added to your 
